Literature DB >> 23835994

Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children.

A Wrotek1, K Pawlik, T Jackowska.   

Abstract

Community-acquired pneumonia (CAP) is a leading single cause of mortality in children under 5 years of age. In search of new diagnostic markers, soluble urokinase plasminogen activator receptor (suPAR) seems to offer promise as a novel clinical tool. The goal of the present study was to assess the relation between suPAR and the severity of CAP. suPAR was measured in 74 (39 males, 35 females) patients aged from 1 month to about 15 years. Correlation between the level of suPAR and inflammatory markers (white blood cell, neutrophil count, C-reactive protein-CRP, and procalcitonin-PCT) was assessed by Spearmann's rank coefficient. We found that the median suPAR level in children with pneumonia was 8.29 ng/mL (range 2.44-18.31 ng/mL). In the multivariate logit model, age and CRP level were statistically important. The older children (age above the median value) had higher suPAR (above the median value) less frequently than the younger children (OR = 0.31), whereas the children with greater CRP values (above the median value) had higher suPAR levels than the children with lower CRP concentration (under the median value) (OR = 4.54). There was also a positive correlation between suPAR and PCT levels. In conclusion, we demonstrate a positive correlation between serum suPAR and the non-specific inflammatory markers CRP and PCT in the community acquired pneumonia in children.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23835994     DOI: 10.1007/978-94-007-6627-3_44

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit.

Authors:  Muhammad S El-Mekkawy; Nagwan Y Saleh; Ahmed A Sonbol
Journal:  Indian J Pediatr       Date:  2016-03-10       Impact factor: 1.967

2.  Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections.

Authors:  Hale Çitlenbik; Emel Ulusoy; Anıl Er; Aykut Çağlar; Fatma Akgül; Tuncay Küme; Durgül Yılmaz; Murat Duman
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-09-17       Impact factor: 1.349

3.  Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD.

Authors:  Gehan Hassan AboEl-Magd; Maaly Mohamed Mabrouk
Journal:  J Bras Pneumol       Date:  2018 Jan-Feb       Impact factor: 2.624

4.  Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study.

Authors:  Tania Siahanidou; Alexandra Margeli; Chrysanthi Tsirogianni; Stavroula Charoni; Maria Giannaki; Eustathios Vavourakis; Athina Charisiadou; Ioannis Papassotiriou
Journal:  Mediators Inflamm       Date:  2014-05-05       Impact factor: 4.711

5.  suPAR and Team Nephrology.

Authors:  Howard Trachtman
Journal:  BMC Med       Date:  2014-05-20       Impact factor: 8.775

Review 6.  Prognostic scores and biomarkers for pediatric community-acquired pneumonia: how far have we come?

Authors:  Samuel N Uwaezuoke; Adaeze C Ayuk
Journal:  Pediatric Health Med Ther       Date:  2017-02-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.